Celsus Therapeutics Plc Announces Formation of New Dermatology Scientific Advisory Board
GlobeNewswire - Mon Apr 07, 6:30AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology Scientific Advisory Board (SAB). The SAB is comprised of:
Celsus Therapeutics Plc to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8th, at 3:40 p.m. Eastern Daylight Time at the Westin Grand Central Hotel in New York.
Celsus Therapeutics Provides Year End 2013 Financial Results and Corporate Highlights
GlobeNewswire - Mon Mar 24, 3:05PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, today announced its financial results and provided a review of the twelve month period ended December 31, 2013.
Celsus Therapeutics Provides Update on MRX-6 From FDA Pre-IND Meeting
GlobeNewswire - Tue Mar 11, 3:05PM CDT
-- Celsus completes Type B pre-IND meeting with FDA for MRX-6 cream in atopic dermatitis
Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Celsus Therapeutics to Present at the 2014 BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 6:30AM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 2014 BIO CEO & Investor Conference on Monday, February 10, at 4:00 p.m. Eastern Standard Time at the Waldorf Astoria in New York.
Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional ADSs
GlobeNewswire - Wed Feb 05, 3:05PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously announced public offering of 1,533,333 American Depository Shares ("ADSs"
Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ
GlobeNewswire - Thu Jan 30, 4:32PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs"